(E)-heptacos-7-en-5-ol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-heptacos-7-en-5-ol
• 化学式: C₂₇H₅₄O
• 分子量: 394.7
• InChiKey: LOFXDOMNAZLWSH-WCWDXBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  12.4
• 重原子数：
  28
• 可旋转键数：
  23
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] MITOMYCIN C PRODRUG LIPOSOME FORMULATIONS AND USES THEREOF<br/>[FR] FORMULATIONS DE LIPOSOME DE PROMÉDICAMENT DE MITOMYCINE C ET LEURS UTILISATIONS
  申请人：MALLINCKRODT LLC

  公开号：WO2018089481A1

  公开（公告）日：2018-05-17

  The present invention provides MMC prodrug compounds and liposomal MMC prodrugs and compositions thereof for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid and a MMC prodrug. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid and a MMC prodrug or a pharmaceutically-acceptable salt thereof.

  本发明提供了用于治疗癌症的MMC前药化合物和脂质体MMC前药及其组合物。该组合物包括含有磷脂酰胆碱脂质、固醇、PEG-脂质和MMC前药的脂质体。本发明还提供了用于治疗癌症的脂质体组合物，包括向需要的患者施用脂质体，其中脂质体包括：磷脂酰胆碱脂质；固醇；PEG-脂质和MMC前药或其药用可接受的盐。
• [EN] LIPOSOMAL ELINAFIDE FORMULATIONS AND USES THEREOF<br/>[FR] FORMULATIONS LIPOSOMALES D'ÉLINAFIDE ET UTILISATIONS DE CES DERNIÈRES
  申请人：MALLINCKRODT LLC

  公开号：WO2018106980A1

  公开（公告）日：2018-06-14

  The present invention provides compositions for the treatment of cancer. The compositions include liposomes containing a phosphatidylcholine lipid, a sterol, a PEG-lipid, and elinafide, wherein less than 20% of the elinafide is released in vitro from the liposome within 40 hours. The present invention also provides liposomal compositions for the treatment of cancer comprising administering to a patient in need thereof a liposome, wherein the liposome comprises: a phosphatidylcholine lipid; a sterol; a PEG-lipid; and elinafide, wherein the administration of the liposomal composition has a reduced occurrence of side effects, such as for example, muscle myopathy in the patient.

  本发明提供了用于治疗癌症的组合物。该组合物包括含有磷脂酰胆碱脂质、甾醇、PEG-脂质和依利纳肽的脂质体，其中在40小时内，脂质体中的依利纳肽释放量不到20%。本发明还提供了用于治疗癌症的脂质体组合物，包括向需要治疗的患者给予脂质体，其中脂质体包括：磷脂酰胆碱脂质、甾醇、PEG-脂质和依利纳肽，给予脂质体组合物的治疗具有减少患者副作用的发生，例如肌肉肌无力等。
• Liposomal cisplatin compositions for cancer therapy
  申请人：Mallinckrodt LLC

  公开号：US10039716B2

  公开（公告）日：2018-08-07

  The present invention provides a composition for the treatment of cancer including zwitterionic liposomes consisting essentially of: 50-65 mol % of a phosphatidylcholine lipid, 30-45 mol % of cholesterol, and 2-8 mol % of a PEG-lipid; and cisplatin. Cisplatin is encapsulated in the liposomes in an amount such that the ratio of the total lipid weight to the cisplatin weight is from about 65:1 to about 95:1. Methods for the preparation of liposomal cisplatin and the treatment of cancer are also disclosed.

  本发明提供了一种治疗癌症的组合物，包括主要由以下成分组成的齐聚物脂质体：50-65 摩尔%的磷脂酰胆碱脂质、30-45 摩尔%的胆固醇和 2-8 摩尔%的 PEG 脂质；以及顺铂：50-65摩尔％的磷脂酰胆碱脂质、30-45摩尔％的胆固醇和2-8摩尔％的PEG脂质；以及顺铂。顺铂被包裹在脂质体中，其总重量与顺铂重量之比约为 65:1 至 95:1。还公开了制备脂质体顺铂和治疗癌症的方法。
• Serial filtration to generate small cholesterol-containing liposomes
  申请人：Verily Life Sciences LLC

  公开号：US11246832B2

  公开（公告）日：2022-02-15

  The present invention provides methods and systems for producing liposomes by filtration. The methods include passing a heated lipid suspension through a filter assembly comprising two or more filters connected in series, wherein an orifice is disposed between adjacent filters. The methods and systems can produce liposomes having an average diameter that is less than half the diameter of the filter pores. Further, the methods and systems can produce liposomes with <100 nm average diameter, even when the liposomes comprise at least 30% sterol.

  本发明提供了通过过滤生产脂质体的方法和系统。这些方法包括让加热的脂质悬浮液通过由两个或两个以上串联的过滤器组成的过滤器组件，其中相邻过滤器之间有一个孔。这些方法和系统可产生平均直径小于过滤孔直径一半的脂质体。此外，即使脂质体包含至少 30% 的固醇，这些方法和系统也能产生平均直径小于 100 nm 的脂质体。
• LIPOSOMAL CISPLATIN COMPOSITIONS FOR CANCER THERAPY
  申请人：Mallinckrodt LLC

  公开号：EP2968142A1

  公开（公告）日：2016-01-20